Author: admin
-
McMaster discovery could lead to new treatments for drug-resistant fungal infections
McMaster discovery could lead to new treatments for drug-resistant fungal infections – Faculty of Health Sciences
-
Samsung Makes Enterprise Debut at CES 2026 with Spatial Signage – Samsung Newsroom U.K.
Samsung Electronics, a global leader in technology, today announced that Spatial Signage has been recognized by the Consumer Technology Association (CTA)® as part of the CES Innovation Awards…
Continue Reading
-
Researchers Raise Concerns about Faster Aging, Possible Early-Onset Dementia, for Children and Young Adult Cancer Survivors
Adolescent and young adult cancer survivors age faster than their peers who did not have cancer, according to a new study, which also describes how accelerated aging occurs both at the cellular level and in brain function, such as memory,…
Continue Reading
-
Is ‘Open Stone Surgery with Intraoperative Nephroscopy’ a better alter
Introduction
The global incidence and prevalence of urolithiasis are steadily rising, creating a need for safe, effective, and affordable treatment options.1 This worldwide trend is now nearly the same in both developing and developed countries.
Continue Reading
-
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. ,Jan. 07, 2026 (GLOBE NEWSWIRE) —Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will present at the 44th AnnualJ.P. Morgan Healthcare Conference inSan Francisco onWednesday, January 14, 2026 at9:00 a.m. PT .A live webcast will be available on the Events and Presentations page in the Investors & Media section of Intellia’s website, www.intelliatx.com. A replay of the webcast will be available on Intellia’s website for approximately 30 days.
About
Intellia Therapeutics Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.Intellia Contacts:
Investors:
Jason Fredette Vice President, Investor Relations and Corporate CommunicationsIntellia Therapeutics, Inc.
jason.fredette@intelliatx.comMedia:
Matt Crenson TenBridge Communications
media@intelliatx.com
mcrenson@tenbridgecommunications.com
Source: Intellia Therapeutics, Inc.
Continue Reading
-
Albertsons® Companies, Inc. Reports Third Quarter Fiscal 2025 Results – Albertsons Companies
- Albertsons® Companies, Inc. Reports Third Quarter Fiscal 2025 Results Albertsons Companies
- Albertsons Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Benzinga
- ACI stock Jan 06 2026 pre-market: BMO EPS est $0.67 ahead of results Meyka
- Albertsons’s (NYSE:ACI) Q3 CY2025 Earnings Results: Revenue In Line With Expectations FinancialContent
- Grocer Albertsons lowers annual sales and profit forecast TradingView — Track All Markets
Continue Reading
-
Research on Frailty Trajectories and Factors in Elderly After Percutan
Introduction
Coronary atherosclerotic heart disease, also known as coronary heart disease (CHD), refers to heart conditions caused by the narrowing or obstruction of the coronary arteries due to atherosclerosis, leading to myocardial ischemia or…
Continue Reading
-
Hull trampoline park Rebound to close amid rising costs
For the trampoline park to meet health and safety requirements, a certain number of staff needs to be present.
He said reducing staff was “one thing we won’t ever do to cut costs per health and safety”.
Over 10 years, the business said it had only…
Continue Reading
